You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,975,937

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,975,937

Title:	Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
Abstract:	The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
Inventor(s):	Pavlakis; George N. (Rockville, MD), Felber; Barbara K. (Rockville, MD), Valentin; Antonio (Frederick, MD), Bergamaschi; Cristina (Frederick, MD)
Assignee:	THE UNITED SSTATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC)
Application Number:	14/512,913
Patent Claims:	1. A composition comprising a first IL-15/IL-15R.alpha. heterodimer comprising IL-15 bound to a soluble form of IL-15R.alpha., wherein the soluble form of IL-15R.alpha. comprises amino acids 31 to 200 of SEQ ID NO:20 and is not in the form of an Fc fusion protein; and a second IL-15/IL-15R.alpha.-Fc heterodimer comprising IL-15 bound to an IL-15R.alpha.-Fc fusion protein. 2. A composition comprising an IL-15/IL-15R.alpha. heterodimer comprising IL-15 bound to a soluble form of IL-15R.alpha., wherein the soluble form of IL-15R.alpha. comprises amino acids 31 to 200 of SEQ ID NO:20 and is not in the form of an Fc fusion protein; and a chemotherapeutic agent. 3. The composition of claim 2, wherein the chemotherapeutic agent is an anticancer agent. 4. The composition of claim 3, wherein the anticancer agent is vinblastine, fludarabine, aclarubicin, doxorubicin, exemestane, alefacept, alemtuzumab, pamidronate, idarubicin, or cyclophosphamide.

Details for Patent 9,975,937

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2029-08-14
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2029-08-14
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004	⤷ Try a Trial	2029-08-14
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036	01/30/2003	⤷ Try a Trial	2029-08-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.